Hematopoietic stem cell expansion and gene therapy.

  title={Hematopoietic stem cell expansion and gene therapy.},
  author={Korashon L. Watts and Jennifer E. Adair and Hans-Peter Kiem},
  volume={13 10},
Hematopoietic stem cell (HSC) gene therapy remains a highly attractive treatment option for many disorders, including hematologic conditions, immunodeficiencies including human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), and other genetic disorders such as lysosomal storage diseases. In this review, we discuss the successes, side-effects and limitations of current gene therapy protocols. In addition, we describe the opportunities presented by implementing ex vivo… 

Figures and Tables from this paper


It has been shown that the microRNAs such as miR-125a/b, mi-17 and mi-29a are able to increase the ex vivo expansion of hematopoietic stem cells, which indicates that the gene transfer approach was the most effective method for expansion.

Haematopoietic stem cell reprogramming and the hope for a universal blood product

An overview of the haematopoietic reprogramming methods reported to date is presented, the appropriate historical context is provided and critical insight is offered about where the field stands at present.

An update on gene therapy for lysosomal storage disorders

Gene therapy is still in its infancy with respect to LSDs, however, efficacy and safety has been demonstrated in numerous pre-clinical studies, and promising clinical results suggest that gene therapy treatment for several LSDs is a real possibility.

Engraftment and lineage potential of adult hematopoietic stem and progenitor cells is compromised following short-term culture in the presence of an aryl hydrocarbon receptor antagonist.

It is revealed that in vitro culture of adult HSPC in AhRA maintains but does not increase the number of in vivo engrafting cells and that H SPC expanded in vitro contain defects in lymphopoiesis as assessed in this model system.

A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor.

These studies describe a fundamental enhancement of the CGS expansion platform, identify a novel precursor population in the erythroid/megakaryocytic differentiation pathway of humans, and implicate an erythropoietin-independent, macrophage-associated pathway supporting terminal erythroblasts in this expansion system.

Disrupted Signaling through the Fanconi Anemia Pathway Leads to Dysfunctional Hematopoietic Stem Cell Biology: Underlying Mechanisms and Potential Therapeutic Strategies

The evidence that supports the role of dysfunctional HSC biology in driving the etiology ofFanconi anemia is discussed and the insights gained using such disease models can be translated into potential novel therapeutic strategies for the treatment of the hematologic disorders in FA patients are considered.

Clinical Safety and Applications of Stem Cell Gene Therapy

The latest developments in gene therapy vectors, the stem cell transduction techniques, and the therapeutic applications under investigation are reviewed.

Review: Biomimetic nanofibers in the ex vivo expansion of cord blood-derived hematopoietic stem cells

Scientific evidence provided in this review verifies that the nanofiber niche provides an ideal mimic of the physical microenvironment of HSCs thereby offering great potential for clinical applications.

Chinese Medicine Protein and Peptide in Gene and Cell Therapy.

A critical review on traditional Chinese medicine's proteins and peptides, accompanied with perspectives on the challenges and new directions for future research in this emerging frontier are presented.

Pluripotin facilitates the expansion of hematopoietic stem cells, but restricts the growth of fibroblasts and the proliferation of mesenchymal stem cells from the bone marrow

Intriguingly, Pluripotin treatment inversely changes bone marrow-derived mesenchymal stem cell (MSC) proliferation and lowers fibroblast growth although there is no effect on adipose-derived MSCs.



Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions, and lower toxic metabolites, indicating the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.

Large animal models of hematopoietic stem cell gene therapy

Large animals continue to be useful to evaluate the efficacy and safety of gene therapy, and dogs with hematopoietic diseases have now been cured by HSC gene therapy.

Ten years of gene therapy for primary immune deficiencies.

  • A. AiutiM. Roncarolo
  • Medicine, Biology
    Hematology. American Society of Hematology. Education Program
  • 2009
Following recent advances in preclinical studies, lentiviral vectors are now being translated into new clinical approaches, such as Wiskott-Aldrich Syndrome, and will provide significant advantages in terms of natural gene regulation and reduction in the potential for adverse mutagenic events.

Ex vivo gene transfer and correction for cell-based therapies

This Review highlights the latest developments and the crucial challenges for cell-based therapies, with an emphasis on haematopoietic stem cell gene therapy, which is taken as a representative example given its advanced clinical translation.

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

A gene therapy trial for SCID-X1 was initiated, based on the use of complementary DNA containing a defective gammac Moloney retrovirus-derived vector and ex vivo infection of CD34+ cells, which provided full correction of disease phenotype and clinical benefit.

Survival of the Fittest

How in vivo selection strategies can be used to make stem cell gene therapy applicable to the treatment of a wider scope of genetic diseases and patients is reviewed.

Gene transfer into hematopoietic stem cells: long-term maintenance of in vitro activated progenitors without marrow ablation.

It is suggested that very primitive hematopoietic progenitors are maintained in long-term marrow cultures, where they can be triggered into entering the cell cycle and continue normal programs of proliferation, differentiation, and self-renewal.

Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation.

A serum-free culture containing SCF, TPO, FGF-1, angiopoietin-like 5, and IGFBP2 supports an approximately 20-fold net expansion of repopulating human cord blood HSCs, a number potentially applicable to several clinical processes including HSC transplantation.

T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years

It is concluded here that gene therapy can be a safe and effective addition to treatment for some patients with this severe immunodeficiency disease.

Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells

Mechanistic studies show that SR1 acts by antagonizing the aryl hydrocarbon receptor (AHR) and AHR modulation as a means to induce ex vivo HSC expansion should facilitate the clinical use of HSC therapy.